ProKidney Corp. Enters Material Definitive Agreement
Ticker: PROK · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1850270
| Field | Detail |
|---|---|
| Company | Prokidney Corp. (PROK) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $2.42, $136.7 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-action
TL;DR
ProKidney Corp. signed a big deal on June 11th.
AI Summary
On June 11, 2024, ProKidney Corp. entered into a Material Definitive Agreement. The company, previously known as Social Capital Suvretta Holdings Corp. III, is incorporated in the Cayman Islands and has its principal executive offices in Winston-Salem, North Carolina.
Why It Matters
This filing indicates a significant contractual development for ProKidney Corp., which could impact its operations and future business strategies.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks and obligations for the company, the specifics of which are not detailed in this initial filing.
Key Numbers
- 001-40560 — Commission File Number (Identifies the company's SEC filing series.)
- 98-1586514 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- PROKIDNEY CORP. (company) — Registrant
- Social Capital Suvretta Holdings Corp. III (company) — Former Company Name
- June 11, 2024 (date) — Date of earliest event reported
- 2000 Frontis Plaza Blvd. Suite 250 Winston-Salem , North Carolina 27103 (address) — Principal Executive Offices
FAQ
What is the nature of the Material Definitive Agreement entered into by ProKidney Corp. on June 11, 2024?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on June 11, 2024.
When did ProKidney Corp. change its name from Social Capital Suvretta Holdings Corp. III?
The filing states the Date of Name Change was March 10, 2021.
Where are ProKidney Corp.'s principal executive offices located?
ProKidney Corp.'s principal executive offices are located at 2000 Frontis Plaza Blvd. Suite 250, Winston-Salem, North Carolina 27103.
What is ProKidney Corp.'s fiscal year end?
ProKidney Corp.'s fiscal year end is December 31 (1231).
Under which jurisdiction is ProKidney Corp. incorporated?
ProKidney Corp. is incorporated in the Cayman Islands.
Filing Stats: 972 words · 4 min read · ~3 pages · Grade level 10.4 · Accepted 2024-06-13 09:06:31
Key Financial Figures
- $0.0001 — ch registered Class A ordinary shares, $0.0001 par value per share PROK The Nasdaq
- $2.42 — , at an offering price to the public of $2.42 per share (the "Public Offering"). Unde
- $136.7 m — fering are expected to be approximately $136.7 million, after deducting the underwriting
Filing Documents
- d814183d8k.htm (8-K) — 31KB
- d814183dex11.htm (EX-1.1) — 243KB
- d814183dex51.htm (EX-5.1) — 39KB
- d814183dex101.htm (EX-10.1) — 52KB
- d814183dex991.htm (EX-99.1) — 9KB
- g814183g55h99.jpg (GRAPHIC) — 2KB
- 0001193125-24-160339.txt ( ) — 595KB
- prok-20240611.xsd (EX-101.SCH) — 2KB
- prok-20240611_lab.xml (EX-101.LAB) — 18KB
- prok-20240611_pre.xml (EX-101.PRE) — 11KB
- d814183d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement by and between the Company and Jefferies LLC, J.P. Morgan Securities LLC, and Guggenheim Securities, LLC, dated June 11, 2024. 5.1 Opinion of Walkers (Cayman) LLP. 10.1* Form of Share Purchase Agreement by and between the Company and certain investors, dated June 11, 2024. 23.1 Consent of Walkers (Cayman) LLP (included in Exhibit 5.1). 99.1 Press Release dated June 11, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROKIDNEY CORP. Date: June 13, 2024 By: /s/ James Coulston James Coulston Chief Financial Officer